
Opinion|Videos|March 21, 2025
CGM vs Traditional Monitoring
Experts discuss the clinical and practical factors that guide decision-making when recommending continuous glucose monitoring (CGM) vs traditional glucose monitoring for patients with type 2 diabetes.
Advertisement
Episodes in this series

Video content above is prompted by the following:
What clinical and practical factors guide your decision-making when recommending CGMs versus vs traditional glucose monitoring for patients with type 2 diabetes?
Advertisement
Related to this article

San Francisco experts say payer step edits and weak biologic follow-up slow atopic dermatitis care and point to pharmacy teams and dashboards.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

In the years since the first approval for CAR T-cell therapy, major managed care plans have adopted mechanisms to include these treatments. But many employer-sponsored plans may not be required to cover them, and such treatments are "lasered out."

The updated label now includes phase 3 data comparing aficamten monotherapy with metoprolol in adults with symptomatic obstructive HCM.

Panelists concurred that precision medicine can serve to exacerbate care inequality if not everyone can access these therapeutics.

IL-23 inhibitors linked to lower psoriatic arthritis risk than JAK inhibitors, and IL-17 inhibitors showed higher risk.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy
2
Ribupatide Yields Up to 17.7% Weight Loss in Phase 3 GEMINI-1 Trial
3
GLP-1s Alone Won't Solve Obesity, JAMA Summit Report Says
4
Menopause Benefit Design Should Prioritize Access, Total Cost of Care
5


